Apogee Therapeutics IncNASDAQ:APGE
- LAST PRICE54.4800
- TODAY'S CHANGE (%)-2.3700 (-4.1689%)
- Bid / Lots21.8000/ 2
- Ask / Lots60.0000/ 1
- Open / Previous Close57.7800 / 56.8500
- Day Range
- 52 Week Range
- Volume325,607
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | APGE |
|---|---|---|
| 09:32 ET | 1134 | 57.78 |
| 09:34 ET | 2881 | 57.7 |
| 09:36 ET | 464 | 56.99 |
| 09:38 ET | 10000 | 57.075 |
| 09:39 ET | 9433 | 57.49 |
| 09:41 ET | 29300 | 57.515 |
| 09:45 ET | 200 | 57.47 |
| 09:48 ET | 3188 | 58 |
| 09:50 ET | 6234 | 57.915 |
| 09:52 ET | 500 | 57.71 |
| 09:54 ET | 523 | 57.05 |
| 10:10 ET | 111 | 57.45 |
| 10:12 ET | 100 | 56.55 |
| 10:15 ET | 100 | 56.76 |
| 10:17 ET | 100 | 57.03 |
| 10:21 ET | 100 | 56.72 |
| 10:24 ET | 100 | 56.74 |
| 10:26 ET | 300 | 56.5 |
| 10:30 ET | 359 | 56.32 |
| 10:32 ET | 100 | 56.48 |
| 10:35 ET | 100 | 56.62 |
| 10:37 ET | 900 | 56.405 |
| 10:44 ET | 300 | 56.305 |
| 11:02 ET | 200 | 56.53 |
| 11:04 ET | 100 | 56.545 |
| 11:08 ET | 2300 | 56.9 |
| 11:09 ET | 100 | 56.9 |
| 11:11 ET | 100 | 56.9 |
| 11:13 ET | 504 | 56.93 |
| 11:15 ET | 500 | 56.55 |
| 11:18 ET | 300 | 56.22 |
| 11:22 ET | 200 | 56.1 |
| 11:24 ET | 700 | 55.96 |
| 11:26 ET | 2200 | 55.96 |
| 11:27 ET | 600 | 55.81 |
| 11:29 ET | 400 | 55.68 |
| 11:31 ET | 600 | 55.73 |
| 11:33 ET | 600 | 55.635 |
| 11:42 ET | 200 | 55.67 |
| 11:44 ET | 2100 | 55.42 |
| 11:45 ET | 1050 | 55.55 |
| 11:47 ET | 1200 | 55.3894 |
| 11:49 ET | 200 | 55.49 |
| 11:51 ET | 100 | 55.4 |
| 11:54 ET | 300 | 55.385 |
| 11:56 ET | 1841 | 55.545 |
| 11:58 ET | 4066 | 55.495 |
| 12:00 ET | 100 | 55.48 |
| 12:02 ET | 5800 | 55.49 |
| 12:03 ET | 100 | 55.49 |
| 12:05 ET | 400 | 55.435 |
| 12:07 ET | 400 | 55.37 |
| 12:09 ET | 300 | 55.28 |
| 12:18 ET | 200 | 55.35 |
| 12:21 ET | 200 | 55.35 |
| 12:23 ET | 100 | 55.44 |
| 12:32 ET | 100 | 55.43 |
| 12:38 ET | 300 | 55.25 |
| 12:39 ET | 284 | 55.42 |
| 12:41 ET | 1494 | 55.34 |
| 12:43 ET | 900 | 55.33 |
| 12:50 ET | 100 | 55.37 |
| 12:52 ET | 100 | 55.3175 |
| 12:54 ET | 800 | 55.06 |
| 12:56 ET | 100 | 55.12 |
| 12:57 ET | 100 | 54.99 |
| 12:59 ET | 240 | 54.92 |
| 01:01 ET | 1194 | 54.985 |
| 01:03 ET | 344 | 55 |
| 01:06 ET | 300 | 55.015 |
| 01:08 ET | 1800 | 55.17 |
| 01:10 ET | 401 | 55.18 |
| 01:12 ET | 500 | 55.3 |
| 01:14 ET | 300 | 55.61 |
| 01:19 ET | 300 | 55.57 |
| 01:21 ET | 100 | 55.7 |
| 01:26 ET | 200 | 55.645 |
| 01:28 ET | 501 | 55.36 |
| 01:30 ET | 386 | 55.39 |
| 01:32 ET | 600 | 55.25 |
| 01:33 ET | 300 | 55.385 |
| 01:37 ET | 100 | 55.51 |
| 01:39 ET | 400 | 55.19 |
| 01:42 ET | 200 | 55.29 |
| 01:44 ET | 200 | 55.38 |
| 01:48 ET | 1300 | 55.32 |
| 01:50 ET | 200 | 55.39 |
| 01:51 ET | 200 | 55.25 |
| 01:55 ET | 400 | 55.05 |
| 02:00 ET | 1100 | 55.01 |
| 02:02 ET | 1111 | 55.01 |
| 02:04 ET | 300 | 54.95 |
| 02:06 ET | 100 | 54.88 |
| 02:08 ET | 100 | 54.83 |
| 02:09 ET | 700 | 54.83 |
| 02:11 ET | 100 | 54.86 |
| 02:13 ET | 100 | 54.9744 |
| 02:15 ET | 200 | 54.76 |
| 02:22 ET | 300 | 54.93 |
| 02:26 ET | 200 | 54.86 |
| 02:27 ET | 100 | 54.95 |
| 02:29 ET | 2494 | 54.67 |
| 02:31 ET | 100 | 54.58 |
| 02:33 ET | 100 | 54.5 |
| 02:38 ET | 1040 | 54.59 |
| 02:40 ET | 100 | 54.71 |
| 02:42 ET | 123 | 54.6555 |
| 02:44 ET | 350 | 54.61 |
| 02:47 ET | 1125 | 54.63 |
| 02:51 ET | 300 | 54.58 |
| 02:54 ET | 404 | 54.65 |
| 02:56 ET | 100 | 54.74 |
| 02:58 ET | 420 | 54.7 |
| 03:00 ET | 200 | 54.84 |
| 03:03 ET | 300 | 54.51 |
| 03:05 ET | 3689 | 54.15 |
| 03:07 ET | 698 | 54.29 |
| 03:09 ET | 200 | 54.55 |
| 03:12 ET | 200 | 54.555 |
| 03:14 ET | 300 | 54.37 |
| 03:16 ET | 100 | 54.39 |
| 03:20 ET | 200 | 54.35 |
| 03:21 ET | 600 | 54.27 |
| 03:23 ET | 1539 | 54.4 |
| 03:27 ET | 428 | 54.45 |
| 03:30 ET | 1100 | 54.5 |
| 03:32 ET | 7850 | 54.75 |
| 03:34 ET | 100 | 54.81 |
| 03:36 ET | 574 | 55.13 |
| 03:38 ET | 203 | 55.12 |
| 03:39 ET | 1366 | 55.57 |
| 03:41 ET | 1200 | 55.57 |
| 03:43 ET | 500 | 55.35 |
| 03:45 ET | 1666 | 55.27 |
| 03:48 ET | 668 | 55.18 |
| 03:50 ET | 1219 | 55.39 |
| 03:52 ET | 1445 | 55.2 |
| 03:54 ET | 2350 | 55.08 |
| 03:56 ET | 13201 | 55 |
| 03:57 ET | 9480 | 54.79 |
| 03:59 ET | 56005 | 54.48 |
Sep 12, 2024
Apogee Therapeutics to Participate at the Stifel 2024 Immunology and Inflammation Summit, from 7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
7:00AM ET on Thursday Sep 12, 2024 by Dow Jones
Sep 9, 2024
Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow JonesPress Release: Apogee Therapeutics Appoints Jeff S. Hartness as Chief Commercial Officer, from 7:00AM ET on Monday Sep 09, 2024 by Dow Jones
7:00AM ET on Monday Sep 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Apogee Therapeutics Inc | 3.2B | -24.3x | --- |
Iovance Biotherapeutics Inc | 3.2B | -6.2x | --- |
Dyne Therapeutics Inc | 3.3B | -9.1x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
MoonLake Immunotherapeutics | 3.5B | -61.1x | --- |
Company Information
Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4Rα. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.
Contact Information
- Headquarters
- 221 Crescent St. Building 17, Suite 102bWALTHAM, MA, United States 02453
- Phone
- 650-394-5230
- Fax
- 302-655-5049
Executives
- Independent Chairman of the Board
- Mark Mckenna
- Chief Executive Officer, Director
- Michael Henderson
- Chief Financial Officer
- Jane Henderson
- Chief Medical Officer
- Carl Dambkowski
- Independent Director
- Lisa Bollinger
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.2B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 58.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.25 |
Book Value | $7.86 |
P/E Ratio | -24.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
